ADGRG7

Summary

ADGRG7 (adhesion G protein-coupled receptor G7, HGNC:19241) is a protein-coding gene on chromosome 3q12.2, encoding Adhesion G-protein coupled receptor G7 (Q96K78). Orphan receptor.

Predicted to enable G protein-coupled receptor activity. Predicted to be involved in adenylate cyclase-activating G protein-coupled receptor signaling pathway. Predicted to be located in membrane. Predicted to be active in plasma membrane.

Source: NCBI Gene 84873 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 146 total
• MANE Select transcript: NM_032787

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19241
Approved symbol	ADGRG7
Name	adhesion G protein-coupled receptor G7
Location	3q12.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14454
Ensembl gene	ENSG00000144820
Ensembl biotype	protein_coding
OMIM	612307
Entrez	84873

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000273352, ENST00000475887, ENST00000481361, ENST00000481506, ENST00000493081, ENST00000868805

RefSeq mRNA: 2 — MANE Select: NM_032787 NM_001308362, NM_032787

CCDS: CCDS2938, CCDS77778

Canonical transcript exons

ENST00000273352 — 16 exons

Exon	Start	End
ENSE00000967307	100629598	100629711
ENSE00000967309	100630705	100630809
ENSE00000967311	100633265	100633377
ENSE00000967313	100635677	100635826
ENSE00000967318	100643526	100643633
ENSE00000967320	100645945	100646108
ENSE00000967321	100646569	100646724
ENSE00000967322	100649695	100649807
ENSE00000967323	100654835	100655181
ENSE00001225265	100694744	100695479
ENSE00001225273	100609601	100609971
ENSE00003528101	100659688	100659843
ENSE00003570251	100668949	100669105
ENSE00003570753	100643266	100643405
ENSE00003576823	100637302	100637402
ENSE00003588830	100655899	100655995

Expression profiles

Bgee: expression breadth ubiquitous, 118 present calls, max score 94.64.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1988 / max 105.4681, expressed in 19 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
37623	0.1256	12
37627	0.0264	6
37626	0.0207	5
37624	0.0096	4
202862	0.0086	3
37625	0.0081	4

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	94.64	gold quality
duodenum	UBERON:0002114	90.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.63	gold quality
right lobe of liver	UBERON:0001114	80.50	gold quality
small intestine	UBERON:0002108	78.90	gold quality
small intestine Peyer’s patch	UBERON:0003454	78.89	gold quality
liver	UBERON:0002107	77.73	gold quality
mucosa of transverse colon	UBERON:0004991	75.43	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	74.03	gold quality
rectum	UBERON:0001052	71.41	gold quality
jejunum	UBERON:0002115	70.42	gold quality
colonic mucosa	UBERON:0000317	66.08	gold quality
gall bladder	UBERON:0002110	62.55	gold quality
transverse colon	UBERON:0001157	62.18	gold quality
smooth muscle tissue	UBERON:0001135	61.89	gold quality
vermiform appendix	UBERON:0001154	61.08	gold quality
mucosa of sigmoid colon	UBERON:0004993	61.06	silver quality
intestine	UBERON:0000160	60.49	gold quality
caecum	UBERON:0001153	56.51	gold quality
large intestine	UBERON:0000059	53.78	gold quality
colon	UBERON:0001155	52.80	gold quality
skin of hip	UBERON:0001554	51.28	silver quality
upper leg skin	UBERON:0004262	49.95	gold quality
seminal vesicle	UBERON:0000998	49.61	gold quality
amniotic fluid	UBERON:0000173	47.13	silver quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
mammary duct	UBERON:0001765	42.29	silver quality
endometrium	UBERON:0001295	41.76	gold quality
urinary bladder	UBERON:0001255	41.72	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-75140	yes	143.27
E-GEOD-76312	yes	94.28
E-ANND-3	yes	6.23

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

37 targeting ADGRG7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-297	99.40	69.58	1418
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6739-3P	99.22	68.84	1843
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-371A-5P	99.08	66.51	1914
HSA-MIR-6074	98.89	69.64	2187
HSA-MIR-412-3P	98.86	66.89	712
HSA-MIR-6754-3P	98.84	66.60	889
HSA-MIR-599	98.32	66.99	1037
HSA-MIR-12120	98.05	68.44	1768

Literature-anchored findings (GeneRIF, showing 2)

• An expressed in-frame TRK-fused gene-G-protein-coupled receptor GPR128 is identified in healthy individuals and in patients with myeloproliferative neoplasms. (PMID:19797732)
• Upregulation of mRNA Expression of ADGRD1/GPR133 and ADGRG7/GPR128 in SARS-CoV-2-Infected Lung Adenocarcinoma Calu-3 Cells. (PMID:38786015)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	adgrg7.2	ENSDARG00000071085
danio_rerio	adgrg7.1	ENSDARG00000071088
mus_musculus	Adgrg7	ENSMUSG00000022755
rattus_norvegicus	Adgrg7	ENSRNOG00000001634

Paralogs (42): CALCR (ENSG00000004948), GIPR (ENSG00000010310), ADGRA2 (ENSG00000020181), CALCRL (ENSG00000064989), GLP2R (ENSG00000065325), ADGRF5 (ENSG00000069122), ADGRL1 (ENSG00000072071), ADCYAP1R1 (ENSG00000078549), SCTR (ENSG00000080293), VIPR2 (ENSG00000106018), CRHR2 (ENSG00000106113), GHRHR (ENSG00000106128), ADGRD1 (ENSG00000111452), GLP1R (ENSG00000112164), ADGRG6 (ENSG00000112414), VIPR1 (ENSG00000114812), ADGRL2 (ENSG00000117114), CRHR1 (ENSG00000120088), ADGRB2 (ENSG00000121753), ADGRE5 (ENSG00000123146), ADGRE2 (ENSG00000127507), ADGRE3 (ENSG00000131355), ADGRB3 (ENSG00000135298), PTH2R (ENSG00000144407), ADGRL3 (ENSG00000150471), ADGRA3 (ENSG00000152990), ADGRF1 (ENSG00000153292), ADGRF4 (ENSG00000153294), ADGRG4 (ENSG00000156920), ADGRG5 (ENSG00000159618), PTH1R (ENSG00000160801), ADGRL4 (ENSG00000162618), EVA1C (ENSG00000166979), ADGRF3 (ENSG00000173567), ADGRG2 (ENSG00000173698), ADGRE1 (ENSG00000174837), ADGRD2 (ENSG00000180264), ADGRB1 (ENSG00000181790), ADGRG3 (ENSG00000182885), ADGRA1 (ENSG00000197177)

Protein

Protein identifiers

Adhesion G-protein coupled receptor G7 — Q96K78 (reviewed: Q96K78)

Alternative names: G-protein coupled receptor 128

All UniProt accessions (2): Q96K78, E9PHI0

UniProt curated annotations — full annotation on UniProt →

Function. Orphan receptor.

Subcellular location. Membrane.

Similarity. Belongs to the G-protein coupled receptor 2 family. Adhesion G-protein coupled receptor (ADGR) subfamily.

RefSeq proteins (2): NP_001295291, NP_116176* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000203	GPS	Conserved_site
IPR000832	GPCR_2_secretin-like	Family
IPR017981	GPCR_2-like_7TM	Domain
IPR046338	GAIN_dom_sf	Homologous_superfamily
IPR047938	GPR128_7tmB2	Domain
IPR053066	ADGR_G7	Family
IPR053984	GPR128_N	Domain
IPR053985	GPR128_GAIN_subdom_A	Domain
IPR053986	GPR128_GAIN_subdom_B	Domain
IPR057244	GAIN_B	Domain

Pfam: PF00002, PF01825, PF22257, PF22259, PF22261

UniProt features (34 total): glycosylation site 10, topological domain 8, transmembrane region 7, sequence variant 3, disulfide bond 2, signal peptide 1, chain 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96K78-F1	80.48	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 383–410, 398–412

Glycosylation sites (10): 82, 159, 178, 191, 247, 261, 312, 316, 387, 413

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 32 (showing top): ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GSE13522_WT_VS_IFNG_KO_SKIN_DN, chr3q12, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, MIKKELSEN_MEF_ICP_WITH_H3K27ME3, GOBP_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GSE13547_WT_VS_ZFX_KO_BCELL_ANTI_IGM_STIM_12H_UP, DIDO1_TARGET_GENES, ZNF2_TARGET_GENES, MIR1297, MIR12120, GSE10463_CD40L_AND_VA347_VS_CD40L_IN_DC_DN, MIR4762_5P, MIR4646_5P

GO Biological Process (3): cell surface receptor signaling pathway (GO:0007166), G protein-coupled receptor signaling pathway (GO:0007186), signal transduction (GO:0007165)

GO Molecular Function (3): G protein-coupled receptor activity (GO:0004930), transmembrane signaling receptor activity (GO:0004888), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
signal transduction	2
G protein-coupled receptor activity	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
signaling receptor activity	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

510 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADGRG7	ADGRA1	Q86SQ6	603
ADGRG7	RNF25	Q96BH1	442
ADGRG7	TMEM244	Q5VVB8	398
ADGRG7	USF3	Q68DE3	375
ADGRG7	NTRK1	P04629	370
ADGRG7	CAPN12	Q6ZSI9	370
ADGRG7	ADGRG4	Q8IZF6	367
ADGRG7	OR51M1	Q9H341	354
ADGRG7	ARL17B	I3L3L1	352
ADGRG7	ARHGAP20	Q9P2F6	344
ADGRG7	FAM221A	A4D161	335
ADGRG7	ADGRG5	Q8IZF4	314
ADGRG7	OR2T29	Q8NH02	314
ADGRG7	DPYS	Q14117	310
ADGRG7	ADGRA3	Q8IWK6	306

IntAct

17 interactions, top by confidence:

A	B	Type	Score
ADGRG7	LDLRAD1	psi-mi:“MI:0915”(physical association)	0.780
LDLRAD1	ADGRG7	psi-mi:“MI:0915”(physical association)	0.780
ADGRG7		psi-mi:“MI:0915”(physical association)	0.560
	ADGRG7	psi-mi:“MI:0915”(physical association)	0.560
ADGRG7	VAPA	psi-mi:“MI:0915”(physical association)	0.560
ADGRG7	SORT1	psi-mi:“MI:0915”(physical association)	0.560
ADGRG7	LDLRAD1	psi-mi:“MI:0915”(physical association)	0.000
ADGRG7	VAPA	psi-mi:“MI:0915”(physical association)	0.000
ADGRG7	SORT1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (6): GPR128 (Two-hybrid), LDLRAD1 (Two-hybrid), GPR128 (Two-hybrid), GPR128 (Two-hybrid), GPR128 (Two-hybrid), LDLRAD1 (Two-hybrid)

ESM2 similar proteins: A7E2Z9, A8K7I4, B7ZSK1, C6KFA3, P07911, P15396, P17301, P19218, P52787, P53710, Q14CN2, Q16819, Q1WIM2, Q2TU62, Q5T601, Q5VV43, Q5Y4N8, Q61549, Q62469, Q62929, Q66IR0, Q6DJ83, Q6F3F9, Q6PT52, Q6Q473, Q6QMG1, Q6YHK3, Q70VB1, Q862Z3, Q86SQ4, Q8BGZ8, Q8BLQ9, Q8BM96, Q8CJ11, Q8CJ12, Q8IZP9, Q8K4Z6, Q8N3J6, Q8TCW7, Q91X17

Diamond homologs: A6QLU6, B7ZCC9, C6KFA3, G5ECX0, O88917, O88923, O95490, O97817, O97827, O97831, P05451, P43137, P48960, Q14246, Q2Q421, Q2Q426, Q5R7Y0, Q5T601, Q5Y4N8, Q61549, Q6QNK2, Q7SY09, Q80T32, Q80TS3, Q86SQ3, Q86SQ4, Q8CJ11, Q8CJ12, Q8IZF6, Q8IZP9, Q8SQA4, Q8VEC3, Q91ZE5, Q923X1, Q96K78, Q9BY15, Q9ESC1, Q9HAR2, Q9HBW9, Q9UHX3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

146 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	118
Likely benign	12
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

2227 predictions. Top by Δscore:

Variant	Effect	Δscore
3:100629694:GAC:G	donor_gain	1.0000
3:100637296:TGGCA:T	acceptor_loss	1.0000
3:100637297:GGCA:G	acceptor_loss	1.0000
3:100637298:GCAG:G	acceptor_loss	1.0000
3:100637299:CA:C	acceptor_loss	1.0000
3:100637300:A:AG	acceptor_gain	1.0000
3:100637300:AGG:A	acceptor_loss	1.0000
3:100637301:G:GC	acceptor_gain	1.0000
3:100637400:AACG:A	donor_loss	1.0000
3:100637401:AC:A	donor_gain	1.0000
3:100637401:ACG:A	donor_loss	1.0000
3:100637402:CGT:C	donor_loss	1.0000
3:100637403:G:GC	donor_loss	1.0000
3:100637403:G:GG	donor_gain	1.0000
3:100637404:TAA:T	donor_loss	1.0000
3:100645940:TATA:T	acceptor_loss	1.0000
3:100645941:ATAG:A	acceptor_loss	1.0000
3:100645942:T:G	acceptor_gain	1.0000
3:100645943:A:AG	acceptor_gain	1.0000
3:100645943:AGATT:A	acceptor_loss	1.0000
3:100645944:G:GA	acceptor_gain	1.0000
3:100646107:AGGT:A	donor_loss	1.0000
3:100646108:GGTG:G	donor_loss	1.0000
3:100646109:G:GG	donor_gain	1.0000
3:100646109:GT:G	donor_loss	1.0000
3:100646567:A:AG	acceptor_gain	1.0000
3:100646568:G:GA	acceptor_gain	1.0000
3:100646568:GTAC:G	acceptor_gain	1.0000
3:100646568:GTACA:G	acceptor_gain	1.0000
3:100646601:T:G	acceptor_gain	1.0000

AlphaMissense

5234 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:100629702:T:A	C74S	0.997
3:100629703:G:C	C74S	0.997
3:100646637:G:C	W393C	0.997
3:100646637:G:T	W393C	0.997
3:100629702:T:C	C74R	0.994
3:100629669:T:A	C63S	0.993
3:100629670:G:C	C63S	0.993
3:100629704:T:G	C74W	0.991
3:100633291:T:A	C121S	0.990
3:100633292:G:C	C121S	0.990
3:100633293:C:G	C121W	0.990
3:100669019:T:A	W684R	0.990
3:100669019:T:C	W684R	0.990
3:100629636:T:A	C52S	0.989
3:100629637:G:C	C52S	0.989
3:100629669:T:C	C63R	0.989
3:100646635:T:A	W393R	0.989
3:100646635:T:C	W393R	0.989
3:100629703:G:T	C74F	0.988
3:100646650:T:A	C398S	0.988
3:100646651:G:C	C398S	0.988
3:100646713:G:C	A419P	0.988
3:100655082:T:A	W543R	0.988
3:100655082:T:C	W543R	0.988
3:100629689:G:C	W69C	0.987
3:100629689:G:T	W69C	0.987
3:100629703:G:A	C74Y	0.987
3:100646616:G:C	W386C	0.987
3:100646616:G:T	W386C	0.987
3:100629675:T:A	C65S	0.986

dbSNP variants (sampled 300 via entrez): RS1000004829 (3:100642986 T>C), RS1000028992 (3:100692017 A>G), RS1000032965 (3:100616989 T>A,C), RS1000038121 (3:100626690 T>C), RS1000057429 (3:100670061 C>G), RS1000077932 (3:100668284 G>A), RS1000190252 (3:100653010 G>A,T), RS1000204635 (3:100614739 C>A,G), RS1000253296 (3:100624515 G>T), RS1000283046 (3:100663369 A>T), RS1000315068 (3:100620275 A>G), RS1000329827 (3:100647497 A>T), RS1000394156 (3:100674471 A>G), RS1000464792 (3:100659130 T>G), RS1000473406 (3:100615023 C>T)

Disease associations

OMIM: gene MIM:612307 | disease phenotypes: MIM:189800

GenCC curated gene-disease

Mondo (1): preeclampsia (MONDO:0005081)

Orphanet (1): Preeclampsia (Orphanet:275555)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_434	Refractive error	5.000000e-25

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs117308378	ADGRG7		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Adhesion Class GPCRs

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	2
methyleugenol	decreases expression	1
quercitrin	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
CGP 52608	affects binding, increases reaction	1
theaflavin-3,3’-digallate	affects expression	1
Cadmium	decreases expression	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment	1
N-Nitrosopyrrolidine	decreases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial